



TREATMENT PRACTICES, COST OF TREATMENT AND ITS IMPLICATIONS IN THE MANAGEMENT OF HYPERTENSION AT SHREE BIRENDRA HOSPITAL

Dr. Ayush Rauniyar Lecturer, Department of Pharmacology KIST Medical College and Teaching Hospital





BACKGROUND

- Hypertension is the most common cardiovascular disease.
- It is also the principal cause of stroke, myocardial infarction and sudden cardiac death.
- Shree Birendra Hospital (SBH) has been giving its medical services to the army veterans, army staffs and its families.
- The treatment is free of cost to the army patients and to army families.





OBJECTIVE

• To analyze the prescription pattern and cost of therapy of hypertension (at the time of **first day** of presentation) in patients visiting OPD/emergency of SBH.



METHODOLOGY



- Design Prospective observational study
- Site SBH Medicine OPD/Emergency
- Duration 28th April 2019 to 8th November 2019 (6 months)
- Inclusion criteria
 - Newly diagnosed hypertensive patients of all age group without comorbidities
- Exclusion criteria
 - Old hypertensive patients with or without co-morbidities
 - New hypertensive patients with co-morbidities
- Consent Informed written consent
- Data collection Designed proforma sheet

New hypertensive patients without comorbidities taken



Data recording of BP, Investigations and prescription of DAY 1 on proforma sheet



Categorization of patient according to JNC-8

- Type of therapy (Mono/Poly/Non-Drug)
- Cost of drugs calculated

Cost of investigations (CBC, RFT, Lipid Profile, Urine) and drugs obtained from hospital



Cost of drug calculated by – *Unit price of drug x Frequency of the dose* (od/bd/tds) for DAY 1



Overall cost of treatment for DAY -1 calculated by –

Cost of drug + cost of investigations


* The cost of drug and investigations are paid by the hospital itself for the patient






RESULTS - Demography

Total Patients - 60










RESULTS – Age group distribution

Age group (years)	Pre hypertension	Stage 1	Stage 2	Hypertensive crisis
31 – 35	7	17	7	-
36 – 40	2	4	6	1





RESULTS – Types of treatment







RESULTS – Drugs given as monotherapy

	AMLODIPINE	LOSARTAN	OLMESARTAN	PROPRANOLOL	ATORVASTATIN
Pre- hypertensio n	3	1	-	-	1
Stage 1	7	1	1	1	-
Stage 2	7	-	-	-	-
Hypertensiv e crisis		-	-	-	-





RESULTS - Drugs given as polytherapy (OPD + emergency)

Drug	Pre- hypertension	Stage 1	Stage 2	Hypertensive crisis	
Amlodipine + Losartan (FDC – Fixed Dose Combination)	1	2	5	4	
Losartan + Hydrochlorthiazide (FDC)	-	2	-	1	
Telmisartan + Hydrchlorthiazide (FDC)	-	1	1	-	
Amlodipine 10mg + Atorvastatin 40mg	-	-	-	1	





RESULTS – Injectable drugs given in emergency

Drugs	Blood Pressure (mm/Hg)	Number of patients
Inj. Frusemide	220/100 200/110 200/110 180/110	4
Inj. Torsemide	220/100	1
Inj. Labetalol	220/150	1



RESULTS – Cost of treatment for DAY 1 in monotherapy (OPD)



DRUG	Per Unit cost	Cost of investigations	Total COST (per pt.)
AMLODIPINE 10mg	Rs. 0.43	Rs. 384.72	Rs. 385.15
LOSARTAN 25mg	Rs. 1.0	Rs. 384.72	Rs. 385.72
OLMESARTAN 20mg	Rs. 3.29	Rs. 384.72	Rs. 388.01
PROPRANOLOL 10mg	Rs. 0.80	Rs. 384.72	Rs. 385.52
ATORVASTATIN 20mg	Rs. 2.0	Rs. 384.72	Rs. 386.72





RESULTS – Cost of treatment for DAY 1 in Polytherapy (OPD)

FDC →	Amlodipine + Losartan	Losartan + Hydrochlorthiazide	Telmisartan + Hydrochlorthiazide
Per unit cost	Rs. 1.20	Rs. 1.29	Rs. 17.0
TOTAL COST (per unit + investigations) →	Rs. 385.92	Rs. 386.01	Rs. 401.72



RESULTS – Cost of treatment for DAY 1 in monotherapy (emergency ward)



Regimen prescribed	Cost of drug + Cost of investigations (Rs)	Total Cost
Inj. Frusemide 40mg (i.v stat) + Tab AMLODIPINE + LOSARTAN (FDC) (OD)	8.80 + 1.20 + 384.72	Rs. 394.72
Inj. Torsemide 10mg (i.v stat) + Tab AMLODIPINE 10mg OD + Tab ATORVASTATIN 40mg OD	3.0 + 3.29 + 11.01 + 384.72	Rs. 402.2
Inj. Labetalol 20mg (i.v stat) + Tab AMLODIPINE + LOSARTAN OD (FDC)	366.0 + 1.20 + 384.72	Rs. 751.92
Inj. Frusemide 40mg (i.v stat) + Tab LOSARTAN + HYDROCHLORTHIAZIDE (FDC)	8.8 + 1.29	Rs. 394.81



CONCLUSION (Rates applicable to SBH only)



```
    OLMESARTAN

                                       LOSARTAN
     Rs. 3.29/unit
                                        Rs 1.0/unit
• AMLODIPINE 10mg
                                   AMLODIPINE 5mg
     Rs. 3.29/unit
                                       Rs. 0.43/unit
• ATORVASTATIN 40mg
                                ATORVASTATIN 20mg
                                        Rs. 2.0/unit
     Rs. 11.0/unit
                           3x
                                Inj. TORSEMIDE 10mg
• Inj. FRUSEMIDE 40mg
     Rs. 8.8/unit
                                        Rs.3.0/unit
```

• FDCs (**Telmisartan + Hydrochlorthiazide**) >>>> FDCs (**Amlodipine + Losartan**)

Rs. 17.0/unit

Rs. 17.0/unit





TAKE AWAY MESSAGE

- Maximum patients in age group (31-40) → <u>early lifestyle</u> <u>changes</u>
- Calcium channel blockers lowers BP >>> Diuretics
- Torsemide >>>Frusemide (Torsemide → increased bioavailability, longer half-life, beneficial effects on myocardial fibrosis, the neurohormonal axis, and ventricular structure)
- Among ARBs → Olmesartan >> Telmisartan = Losartan

ACKNOWLEDGEMENTS







Shree Birendra Hospital, Chauni



Prof. Dr. Kumud Kumar Kafle

Ex-Dean MMC,IOM

Ex-HOD – Dept. of Pharmacology - IOM, NAIHS

and KIST Medical College



Assoc. Prof. Dr. Sammod Acharya HOD – Dept. of Pharmacology, NAIHS



Prof. Dr. Nisha Jha *HOD – KIST Medical College*





Dr. Ayush RauniyarMBBS (COMS, Bharatpur, Nepal)MD (Clinical Pharmacolology) (NAIHS, Kathmandu)

Ex-faculty (Dept. of Pharmacology) at National Medical College Ex-IRC member at National Medical College

Currently faculty and IRC member at KIST Medical College (Dept. of Pharmacology)

THANK YOU